ReNeuron Group plc (RNUGF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.58 Million GBP | -38.29% |
| 2022 | 7.43 Million GBP | 15.34% |
| 2021 | 6.44 Million GBP | -9.88% |
| 2020 | 7.15 Million GBP | -3.73% |
| 2019 | 7.43 Million GBP | 24.89% |
| 2018 | 5.94 Million GBP | 4.31% |
| 2017 | 5.7 Million GBP | 35.82% |
| 2016 | 4.19 Million GBP | 42.29% |
| 2015 | 2.95 Million GBP | 22.86% |
| 2014 | 2.4 Million GBP | 82.8% |
| 2013 | 1.31 Million GBP | -14.01% |
| 2012 | 1.52 Million GBP | 13.94% |
| 2011 | 1.34 Million GBP | 94.07% |
| 2010 | 691 Thousand GBP | -75.92% |
| 2009 | 2.87 Million GBP | 250.43% |
| 2008 | 819 Thousand GBP | 0.49% |
| 2007 | 815 Thousand GBP | -38.26% |
| 2006 | 1.32 Million GBP | -28.14% |
| 2005 | 1.83 Million GBP | 77.83% |
| 2004 | 1.03 Million GBP | -11.86% |
| 2003 | 1.17 Million GBP | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4 Million GBP | -12.77% |
| 2024 Q2 | 4 Million GBP | 0.0% |
| 2023 Q1 | 6.74 Million GBP | -9.28% |
| 2023 Q2 | 6.74 Million GBP | 0.0% |
| 2023 Q3 | 4.58 Million GBP | -31.98% |
| 2023 FY | 4.58 Million GBP | -38.29% |
| 2023 Q4 | 4.58 Million GBP | 0.0% |
| 2022 Q2 | 7.28 Million GBP | 0.0% |
| 2022 Q3 | 7.43 Million GBP | 2.12% |
| 2022 FY | 7.43 Million GBP | 15.34% |
| 2022 Q1 | 7.28 Million GBP | 12.95% |
| 2022 Q4 | 7.43 Million GBP | 0.0% |
| 2021 Q1 | 8.78 Million GBP | 22.76% |
| 2021 FY | 6.44 Million GBP | -9.88% |
| 2021 Q4 | 6.44 Million GBP | 0.0% |
| 2021 Q3 | 6.44 Million GBP | -26.59% |
| 2021 Q2 | 8.78 Million GBP | 0.0% |
| 2020 Q2 | 7.98 Million GBP | 0.0% |
| 2020 Q1 | 7.98 Million GBP | 7.48% |
| 2020 Q4 | 7.15 Million GBP | 0.0% |
| 2020 FY | 7.15 Million GBP | -3.73% |
| 2020 Q3 | 7.15 Million GBP | -10.43% |
| 2019 FY | 7.43 Million GBP | 24.89% |
| 2019 Q1 | 5.2 Million GBP | -12.56% |
| 2019 Q2 | 5.2 Million GBP | 0.0% |
| 2019 Q3 | 8.26 Million GBP | 58.9% |
| 2019 Q4 | 7.43 Million GBP | -10.11% |
| 2018 Q2 | 6.33 Million GBP | 0.0% |
| 2018 FY | 5.94 Million GBP | 4.31% |
| 2018 Q1 | 6.33 Million GBP | 11.13% |
| 2018 Q4 | 5.94 Million GBP | 0.0% |
| 2018 Q3 | 5.94 Million GBP | -6.14% |
| 2017 FY | 5.7 Million GBP | 35.82% |
| 2017 Q4 | 5.7 Million GBP | 0.0% |
| 2017 Q3 | 5.7 Million GBP | 24.25% |
| 2017 Q2 | 4.59 Million GBP | 0.0% |
| 2017 Q1 | 4.59 Million GBP | 9.31% |
| 2016 Q2 | 3.12 Million GBP | 0.0% |
| 2016 FY | 4.19 Million GBP | 42.29% |
| 2016 Q1 | 3.12 Million GBP | 5.83% |
| 2016 Q3 | 4.19 Million GBP | 34.45% |
| 2016 Q4 | 4.19 Million GBP | 0.0% |
| 2015 FY | 2.95 Million GBP | 22.86% |
| 2015 Q1 | 2.19 Million GBP | -8.7% |
| 2015 Q4 | 2.95 Million GBP | 0.0% |
| 2015 Q3 | 2.95 Million GBP | 34.56% |
| 2015 Q2 | 2.19 Million GBP | 0.0% |
| 2014 Q2 | 1.49 Million GBP | 11.12% |
| 2014 FY | 2.4 Million GBP | 82.8% |
| 2014 Q4 | 2.4 Million GBP | 0.0% |
| 2014 Q3 | 2.4 Million GBP | 60.24% |
| 2014 Q1 | 1.34 Million GBP | 2.66% |
| 2013 Q2 | 1.16 Million GBP | 0.0% |
| 2013 Q3 | 1.16 Million GBP | 0.0% |
| 2013 FY | 1.31 Million GBP | -14.01% |
| 2013 Q4 | 1.31 Million GBP | 12.89% |
| 2012 Q4 | 1.52 Million GBP | 0.0% |
| 2012 Q2 | 937 Thousand GBP | 0.0% |
| 2012 FY | 1.52 Million GBP | 13.94% |
| 2011 Q2 | 1.19 Million GBP | 0.0% |
| 2011 FY | 1.34 Million GBP | 94.07% |
| 2011 Q4 | 1.34 Million GBP | 0.0% |
| 2010 FY | 691 Thousand GBP | -75.92% |
| 2010 Q4 | 691 Thousand GBP | 0.0% |
| 2010 Q2 | 669 Thousand GBP | 0.0% |
| 2009 Q4 | 2.87 Million GBP | 0.0% |
| 2009 Q2 | 1.59 Million GBP | 0.0% |
| 2009 FY | 2.87 Million GBP | 250.43% |
| 2008 Q4 | 819 Thousand GBP | 0.0% |
| 2008 Q2 | 1.11 Million GBP | 0.0% |
| 2008 FY | 819 Thousand GBP | 0.49% |
| 2007 Q4 | 815 Thousand GBP | 0.0% |
| 2007 Q2 | 1.38 Million GBP | 0.0% |
| 2007 FY | 815 Thousand GBP | -38.26% |
| 2006 FY | 1.32 Million GBP | -28.14% |
| 2006 Q2 | 1.38 Million GBP | 0.0% |
| 2006 Q4 | 1.32 Million GBP | 0.0% |
| 2005 Q4 | 1.83 Million GBP | 0.0% |
| 2005 FY | 1.83 Million GBP | 77.83% |
| 2005 Q2 | 559 Thousand GBP | 0.0% |
| 2004 FY | 1.03 Million GBP | -11.86% |
| 2003 FY | 1.17 Million GBP | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 91.393% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 52.119% |
| SQZ Biotechnologies Company | 50.03 Million USD | 90.831% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 93.669% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 92.226% |
| Mesoblast Limited | 188.44 Million USD | 97.565% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -19.125% |
| Genus plc | 485 Million USD | 99.054% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 21.474% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -82.329% |
| Marizyme, Inc. | 26.67 Million USD | 82.801% |
| ContraFect Corporation | 32.53 Million USD | 85.897% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -20.737% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -131.564% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -19.865% |
| Intellipharmaceutics International Inc. | 12 Million USD | 61.795% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 61.047% |
| MultiCell Technologies, Inc. | 1617.67 USD | -283517.796% |
| Accustem Sciences Inc. | 1.07 Million USD | -325.114% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.074% |
| EV Biologics, Inc. | 2.11 Million USD | -116.92% |
| Q BioMed Inc. | 8.13 Million USD | 43.587% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 94.468% |
| Neon Bloom, Inc. | 1.22 Million USD | -274.16% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 10.844% |
| Biomind Labs Inc. | 1.49 Million USD | -206.15% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.12% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 75.07% |
| Skye Bioscience, Inc. | 14.07 Million USD | 67.397% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -128.244% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3128.826% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 51.531% |
| IMV Inc. | 37.93 Million USD | 87.905% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2181.271% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 20.151% |
| GB Sciences, Inc. | 5.41 Million USD | 15.312% |
| Alpha Cognition Inc. | 7.16 Million USD | 35.964% |
| HST Global, Inc. | 593.59 Thousand USD | -672.92% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Halberd Corporation | 728.71 Thousand USD | -529.598% |
| Enzolytics Inc. | 365.26 Million USD | 98.744% |
| Resverlogix Corp. | 67.39 Million USD | 93.192% |
| Affymax, Inc. | 8.87 Million USD | 48.281% |
| SYBLEU INC | 681.41 Thousand USD | -573.307% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -447.016% |
| argenx SE | 444.95 Million USD | 98.969% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 93.876% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -167.678% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 61.455% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -25.179% |
| AVAX Technologies, Inc. | 3.99 Million USD | -14.88% |
| Zenith Capital Corp. | 27.56 Thousand USD | -16541.88% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.654% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1822.448% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -22.861% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -573.879% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.136% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 49.26% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -6755.025% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -219.975% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 90.872% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -69.196% |
| BioStem Technologies, Inc. | 15.9 Million USD | 71.153% |
| ONE Bio Corp. | 27.49 Million USD | 83.314% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -887.306% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -16624.383% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -264.36% |
| Agentix Corp. | 2.51 Million USD | -82.748% |
| LadRx Corporation | 2.2 Million USD | -108.495% |
| Cell Source, Inc. | 15.8 Million USD | 70.974% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -10164.901% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.934% |
| Regen BioPharma, Inc. | 5.45 Million USD | 15.934% |
| NovAccess Global Inc. | 7.86 Million USD | 41.634% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 81.46% |
| Itoco Inc. | 1.65 Million USD | -177.531% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -123.634% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 24.153% |
| Kadimastem Ltd | 3.5 Million USD | -30.904% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -988.318% |
| CytoDyn Inc. | 127.89 Million USD | 96.413% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -10876.339% |
| Mobile Lads Corp. | 1.31 Million USD | -249.297% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -192.905% |
| Qrons Inc. | 1.48 Million USD | -208.186% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 58.462% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -467.264% |
| Rebus Holdings, Inc. | 5.24 Million USD | 12.476% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 24.81% |
| International Stem Cell Corporation | 5.27 Million USD | 13.057% |
| Bioxytran, Inc. | 3.24 Million USD | -41.191% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -633.131% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 0.631% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 88.809% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 79.394% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -126.525% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 16.247% |
| Neutra Corp. | 973.52 Thousand USD | -371.275% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 84.187% |
| PureTech Health plc | 125.58 Million USD | 96.347% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -22.115% |
| IXICO plc | 1.9 Million USD | -141.437% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 77.651% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 95.56% |
| CSL Limited | 18.62 Billion USD | 99.975% |
| Cellectis S.A. | 249.36 Million USD | 98.16% |